THE BLOG

Expert views on Analgesic News

All Posts

Sep 4
1 min

How to improve innovation in analgesic development: Poster presented at IASP virtual Meeting 2020.

Increasing innovation within analgesic R&D is key to identify new treatment options for millions of pain patients. I am delighted Analges...

103 viewsWrite a comment

Peripherally acting phase 1 pain drug acquired in $940Million deal.

mark field

Aug 26
1 min

Peripherally acting phase 1 pain drug acquired in $940Million deal.

Yesterday (25th Aug 2020) saw the announcement that ACADIA Pharmaceuticals acquires privately held Dallas, TX-based CerSci Therapeutics, ...

213 viewsWrite a comment

Unity Bio's novel pain drug fails in OA. Did they miss out by not using a precision approach?

mark field

Aug 18
2 min

Unity Bio's novel pain drug fails in OA. Did they miss out by not using a precision approach?

"Unity Biotechnology announced the 12-week results from the Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor, in patients with ...

50 viewsWrite a comment

FDA approves Trevena’s Mu opioid for Acute pain.

mark field

Aug 11
2 min

FDA approves Trevena’s Mu opioid for Acute pain.

Back in January 2020 the FDA had a number of expert panels voting on opioid drugs – ultimately giving negative feedback for the class. So...

105 viewsWrite a comment

NICE guidance on chronic pain could prevent patients receiving life altering treatments

mark field

Aug 7
2 min

NICE guidance on chronic pain could prevent patients receiving life altering treatments

Nice guidance on chronic pain creates wrong messages and potentially stops patients receiving life altering medication. This week NICE (t...

160 viewsWrite a comment

P2X3 cough drug: Negative Ph II = 70% loss of stock price but severe patient group may show the way.

mark field

Jul 7
2 min

P2X3 cough drug: Negative Ph II = 70% loss of stock price but severe patient group may show the way.

Targeting the right patient population in clinical trials is key to avoiding a false negative and giving a medicine the best chance of su...

81 viewsWrite a comment

Biogen ready to write-off Nav1.7 assets in pain?

mark field

May 26
3 min

Biogen ready to write-off Nav1.7 assets in pain?

The last annual report for Biogen indicates worrying signs for the future development of the latest stage Nav1.7 compound Vixotrigine.

627 viewsWrite a comment

Revolutionising pain R&D by developing Precision Analgesics

mark field

May 12
1 min

Revolutionising pain R&D by developing Precision Analgesics

Presentation by Mark J. Field at SMI Pain Therapeutics Meeting 12th May 2020. You can find a copy of the presentation above. It covers th...

120 viewsWrite a comment

COVID19: creating a new era for 'Citizen Science'

mark field

Apr 20
4 min

COVID19: creating a new era for 'Citizen Science'

"Citizen science" is defined as "scientific work undertaken by members of the general public, often in collaboration with or under the di...

27 viewsWrite a comment

P2X3 receptor antagonists pass Phase 3 trials for cough – potential also in pain?

mark field

Mar 20
2 min

P2X3 receptor antagonists pass Phase 3 trials for cough – potential also in pain?

P2X3 receptor channels are attractive therapeutic targets as they are expressed in sensory neurons, activated by extracellular ATP and se...

149 viewsWrite a comment

Which companies are interested in Pain? The useful analytics below LinkedIn likes & comments.

mark field

Mar 17
2 min

Which companies are interested in Pain? The useful analytics below LinkedIn likes & comments.

I believe LinkedIn is a great source for keeping up to date with content which can be tailored to be most relevant to you. Over the past ...

138 viewsWrite a comment

Is this still a relevant target for new pain treatments: the α2δ (Alpha2Delta) Ca2+ channel?

mark field

Feb 21
3 min

Is this still a relevant target for new pain treatments: the α2δ (Alpha2Delta) Ca2+ channel?

The traditional approach to analgesic development could be described as 'exceptionally challenging', with a clinical success rate of arou...

86 viewsWrite a comment

Has a new study found a personalized approach for Nav1.7? 'Precision Analgesics' may be a better bet

mark field

Feb 10
4 min

Has a new study found a personalized approach for Nav1.7? 'Precision Analgesics' may be a better bet

The difficulties of pain research are highlighted well by the tale of the Nav1.7 sodium channel, which was thought to be the ‘holy grail’...

71 viewsWrite a comment

So Pfizer & Lilly do ask FDA to approve Tanezumab for OA pain...

mark field

Feb 6
3 min

So Pfizer & Lilly do ask FDA to approve Tanezumab for OA pain...

Just a few months ago some commentators had pronounced the death of Tanezumab and the whole anti-NGF class it leads, following years of d...

233 viewsWrite a comment

Vertex discontinues development of its Nav1.8 pain drug VX-961.

mark field

Feb 3
2 min

Vertex discontinues development of its Nav1.8 pain drug VX-961.

Deep within the Full-Year and Fourth-Quarter 2019 Financial Results for Vertex you can find this statement: “Pain: The company announced ...

971 viewsWrite a comment

Big data & human biomarkers – the era of citizen scientists

mark field

Jan 28
2 min

Big data & human biomarkers – the era of citizen scientists

The probability of a new analgesic making it through clinical development is 2%. Five-times lower than other therapeutic areas. This woef...

20 viewsWrite a comment

Approval of new pain drug shows the path for analgesic innovation

mark field

Jan 28
2 min

Approval of new pain drug shows the path for analgesic innovation

The new Novartis medicine Adakveo® (crizanlizumab)has just been approved by the FDA to reduce frequency of pain crises in individuals liv...

46 viewsWrite a comment

Patient-Inspired R&D – the missing part of patient engagement

mark field

Jan 28
3 min

Patient-Inspired R&D – the missing part of patient engagement

Patient engagement is the ‘hot topic’ within the pharma industry over the last few years, with every company, Biotech, CRO and consultant...

19 viewsWrite a comment

{"items":["5f51fe141f5b870018dc73f8","5f4634ef76163b0017b52ed5","5f3bed2e3c48e00017dcddff","5f328e2608c9b200188dc83d","5f2d229800ac55001754208d","5f0480cac560550017b3af7c","5ecce94ab14cc70017d090dc","5ebac325e9c50300170a1a29","5e9dec360c2bba0017e5f659","5e74b9f054d25a001766fa53","5e70ebd2f1f43b0017def04e","5e4fa2e26edacc00176d0bf0","5e4179f04178f50017227982","5e3c00c7fc54180017854727","5e382a7ddedd8e001724de44","5e30bf597b22bb0017cb8750","5e30bde8eb283900170b0c77","5e30514170f058001703260c"],"styles":{"galleryType":"Columns","groupSize":1,"showArrows":true,"cubeImages":true,"cubeType":"fill","cubeRatio":1.3333333333333333,"isVertical":true,"gallerySize":940,"collageAmount":0,"collageDensity":0,"groupTypes":"1","oneRow":false,"imageMargin":16,"galleryMargin":0,"floatingImages":0,"chooseBestGroup":true,"smartCrop":false,"hasThumbnails":false,"enableScroll":true,"isGrid":true,"isSlider":false,"isColumns":false,"isSlideshow":false,"cropOnlyFill":false,"fixedColumns":1,"enableInfiniteScroll":true,"isRTL":false,"minItemSize":50,"rotatingGroupTypes":"","rotatingCubeRatio":"","gallerySliderImageRatio":1.7777777777777777,"numberOfImagesPerRow":1,"numberOfImagesPerCol":1,"groupsPerStrip":0,"borderRadius":0,"boxShadow":0,"gridStyle":1,"mobilePanorama":false,"placeGroupsLtr":false,"viewMode":"preview","thumbnailSpacings":4,"galleryThumbnailsAlignment":"bottom","isMasonry":false,"isAutoSlideshow":false,"slideshowLoop":false,"autoSlideshowInterval":4,"useCustomButton":false,"bottomInfoHeight":0,"titlePlacement":"SHOW_ON_THE_RIGHT","galleryHorizontalAlign":"center","galleryTextAlign":"center","galleryVerticalAlign":"center","scrollSnap":false,"itemClick":"expand","fullscreen":true,"allowSocial":true,"allowDownload":false,"allowTitle":true,"allowDescription":false,"loveButton":true,"loveCounter":false,"videoPlay":"hover","scrollAnimation":"NO_EFFECT","scrollDirection":0,"overlayAnimation":"FADE_IN","arrowsPosition":0,"arrowsSize":23,"watermarkOpacity":40,"watermarkSize":40,"useWatermark":true,"watermarkDock":{"top":"auto","left":"auto","right":0,"bottom":0,"transform":"translate3d(0,0,0)"},"loadMoreAmount":"all","defaultShowInfoExpand":1,"allowTitleExpand":true,"allowDescriptionExpand":true,"allowLinkExpand":true,"expandInfoPosition":0,"allowFullscreenExpand":true,"fullscreenLoop":false,"galleryAlignExpand":"left","addToCartBorderWidth":1,"addToCartButtonText":"","slideshowInfoSize":200,"playButtonForAutoSlideShow":false,"allowSlideshowCounter":false,"hoveringBehaviour":"NEVER_SHOW","thumbnailSize":120,"magicLayoutSeed":1,"imageHoverAnimation":"NO_EFFECT","calculateTextBoxHeightMode":"AUTOMATIC","calculateTextBoxWidthMode":"PERCENT","textBoxHeight":0,"textBoxWidth":200,"textBoxWidthPercent":50,"textImageSpace":10,"textBoxBorderRadius":0,"textBoxBorderWidth":0,"textsVerticalPadding":0,"textsHorizontalPadding":-30,"titleDescriptionSpace":6,"customButtonText":"","customButtonBorderWidth":1,"customButtonBorderRadius":0,"loadMoreButtonText":"","loadMoreButtonBorderWidth":1,"loadMoreButtonBorderRadius":0,"imageInfoType":"ATTACHED_BACKGROUND","itemBorderWidth":1,"itemBorderRadius":0,"itemEnableShadow":false,"itemShadowBlur":20,"itemShadowDirection":135,"itemShadowSize":10,"imageLoadingMode":"BLUR","expandAnimation":"NO_EFFECT","imageQuality":90,"usmToggle":false,"usm_a":0,"usm_r":0,"usm_t":0,"videoSound":false,"videoSpeed":"1","videoLoop":true,"gallerySizeType":"px","gallerySizePx":940,"allowContextMenu":true,"itemBorderColor":{"value":"#BFBFBF"},"galleryLayout":2,"modifiedGallerySize":true,"selectedLayout":"2|bottom|1|fill|true|0|true","layoutsVersion":2,"selectedLayoutV2":2,"isSlideshowFont":false,"externalInfoHeight":0,"externalInfoWidth":0.5},"container":{"width":940,"galleryWidth":972,"galleryHeight":1440,"scrollBase":0,"height":null}}